




RealRate

PHARMACEUTICAL 2013

Filana Therapeutics INC
Rank 132 of 218



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Filana Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Filana Therapeutics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 53% points. The greatest weakness of Filana Therapeutics INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 137% points.

The company's Economic Capital Ratio, given in the ranking table, is 188%, being 32% points below the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	56,507
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,999
Liabilities, Non-Current	0
Other Assets	352
Other Compr. Net Income	-124
Other Expenses	0
Other Liabilities	33,724
Other Net Income	0
Other Revenues	11,341
Property and Equipment	0
Research and Development	7,605
Selling, General and Administrative Expense	7,182

Output Variable	Value in 1000 USD
Assets	56,859
Liabilities	43,723
Expenses	14,787
Revenues	11,341
Stockholders Equity	13,136
Net Income	-3,446
Comprehensive Net Income	-3,508
BaseVar	63,417
ECR before LimitedLiability	50%
Economic Capital Ratio	188%